AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash DealInvestors Business Daily • 11/30/23
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.Market Watch • 11/30/23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioPRNewsWire • 11/30/23
AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)Seeking Alpha • 11/30/23
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)PRNewsWire • 11/29/23
AbbVie says FDA has granted breakthrough therapy designation to epocritamab for a type of lymphomaMarket Watch • 11/27/23
AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular LymphomaPRNewsWire • 11/27/23